Reimbursement Decisions Logo
Guest | Login/Register
Your foremost guide to global pricing and reimbursement decisions.TM

Canadian Drug Review Reimbursement Decision


Back to Decisions Master Page
  Abilify
Generic aripiprazole
Company Bristol-Myers Squibb Canada
Indication schizophrenia, schizoaffective
Condition Mental and behavioural disorders
Submission Type
Patient Population Aripiprazole has a Health Canada indication for the treatment of schizophrenia and related psychotic disorders, which is the focus of this recommendation. Aripiprazole also has a Health Canada indication for the acute treatment of manic or mixed episodes in bipolar I disorder. It has partial agonist activity at the dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at the serotonin 5-HT2A receptors. The Health Canada-recommended starting dose for aripiprazole is 10 mg to 15 mg once a day, with a maximum daily dose of 30 mg. It is available as 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg tablets.
Status Complete
Date of Recommendation 2011-07-18
Recommendation Summary List with criteria/condition
Recommendation Notes This recommendation supersedes the CEDAC recommendation for this drug and indication dated April 27, 2010.
Recommendation Details The Canadian Expert Drug Advisory Committee (CEDAC) recommends that aripiprazole be listed for the treatment of schizophrenia and schizoaffective disorders in patients who have a contraindication to less expensive antipsychotic agents, or who failed a trial of less expensive antipsychotic agents because of intolerance or lack of response.
Reason for Recommendation At the new submitted price, the average daily cost of treatment with Abilify is within the range of most of the costs of other newer antipsychotic medications currently reimbursed by participating drug plans.
Clinical Report:
Pharmacoeconomic Report:
Final Recommendation Report: CDR clinical report  CADTH-CDR Final Recommendation report

†The information referenced on this page is compiled from publicly available documents published by CADTH and is available through the embedded links.


Back to Decisions Master Page